<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03977363</url>
  </required_header>
  <id_info>
    <org_study_id>CHAD-2019-01</org_study_id>
    <nct_id>NCT03977363</nct_id>
  </id_info>
  <brief_title>The Portuguese Survey on Anticoagulated Patients Register (START-Portugal-Register)</brief_title>
  <acronym>START-Portugal</acronym>
  <official_title>The Portuguese Survey on Anticoagulated Patients Register (START-Portugal-Register)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHAD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association for Innovation and Biomedical Research on Light and Image</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anticoagulants are used to prevent thrombotic events in patients with predisposing factors.
      However, the use of such therapies is associated with bleeding complications, which can be a
      serious safety issue. Thus, it is important to evaluate the safety and effectiveness of such
      therapies based on data collected in clinical practice in order to generate relevant
      scientific data that could be used to support clinical and regulatory decisions.

      This is an open, prospective, multicenter, observational cohort study that aims to
      prospectively record the clinical history of adult patients receiving anticoagulant
      treatment, irrespectively of the prescribed drug and the indication for its use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The Portuguese Survey on anTicoagulated pAtients RegisTer (START-Portugal-Register) is
           an open, prospective, multicenter, observational cohort study that intends to record the
           clinical history of adult patients receiving anticoagulant therapies, providing
           real-world data on the safety and effectiveness of such therapies, as well as to serve
           as the starting point of collaborative clinical studies, enabling their planning and
           execution.

        -  The START-Portugal-Register is designed solely for observational purposes; it is not
           intended to have any influence on the treatment of included patients.

        -  Objectives:

             -  To prospectively record the clinical history of adult patients receiving
                anticoagulant treatment, irrespectively of the prescribed drug and the indication
                for its use.

             -  To enhance the understanding of risks and benefits associated with the use of
                anticoagulant drugs in routine clinical practice;

             -  To prospectively record decisions and reasons guiding physicians' decisions in
                order to manage anticoagulant treatment options in routine clinical practice;

             -  To improve knowledge on the epidemiologic, diagnostic and clinical features of
                thrombotic diseases;

             -  To generate real-world evidence on the safety and effectiveness of anticoagulant
                drugs, therefore contributing to support informed clinical decisions.

        -  The START-Portugal-Register is open to the participation of clinical centers and
           individual physicians that are involved in the management of patients undergoing
           anticoagulant treatment.

        -  Patients who sign the informed consent and fulfil the inclusion/exclusion criteria will
           be enrolled in the study and considered for data analysis.

        -  Follow-up: mandatory for at least 12 months. Nevertheless, a long-term follow-up is
           recommended for patients who receive an indefinite anticoagulation treatment. The
           START-Portugal-Register sets itself an indefinite time limit.

        -  A descriptive analysis will be conducted for all study variables. A propensity score
           model will be applied to compare the safety and efficacy of the different anticoagulant
           treatments.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Incidence of complications</measure>
    <time_frame>At least 12 months of follow-up</time_frame>
    <description>From date of inclusion in the registry until the date of first documented complication or date of death from any cause, whichever came first.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Heart Valve Diseases or Prosthesis</condition>
  <arm_group>
    <arm_group_label>Anticoagulated patients</arm_group_label>
    <description>Patients receiving anticoagulation treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anticoagulant drugs</intervention_name>
    <description>Anticoagulant drugs</description>
    <arm_group_label>Anticoagulated patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The START-Portugal-Register is open to the participation of clinical centers and individual
        physicians (called Participants) that are involved in the management of patients undergoing
        anticoagulant treatment. Participants are required to enroll patients consecutively,
        without any a-priori exclusion criteria other than life-expectancy,lack of availability for
        follow-up or geographical inaccessibility.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥18 years;

          -  Patients who, at the time of inclusion, have been receiving for no more than 30 days
             or are about to start anticoagulation therapy - irrespectively of the prescribed drug,
             the dosage, and the indication for its use;

          -  Availability to sign an informed consent form.

        Exclusion Criteria:

          -  Not available for follow-up and constant monitoring;

          -  Participation in phase II or III clinical studies*;

          -  Life-expectancy &lt;6 months, non-residents in the Participant region, or planning to
             leave in the next 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Batel Marques, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIBILI - Association for Innovation and Biomedical Research on Light and Image</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francisco Batel Marques, PhD</last_name>
    <phone>+351 239 480 138</phone>
    <email>batelmarques@aibili.pt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diogo Mendes, PhD</last_name>
    <phone>+351 239 480 138</phone>
    <email>dmendes@aibili.pt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AIBILI - Association for Innovation and Biomedical Research on Light and Image</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Francisca Almeida</last_name>
      <phone>+351 239 480 113</phone>
      <email>mfalmeida@aibili.pt</email>
    </contact>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <reference>
    <citation>Testa S, Paoletti O, Zimmermann A, Bassi L, Zambelli S, Cancellieri E. The role of anticoagulation clinics in the era of new oral anticoagulants. Thrombosis. 2012;2012:835356. doi: 10.1155/2012/835356. Epub 2012 Oct 14.</citation>
    <PMID>23097696</PMID>
  </reference>
  <reference>
    <citation>Antonucci E, Poli D, Tosetto A, Pengo V, Tripodi A, Magrini N, Marongiu F, Palareti G; START-Register. The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. PLoS One. 2015 May 22;10(5):e0124719. doi: 10.1371/journal.pone.0124719. eCollection 2015.</citation>
    <PMID>26001109</PMID>
  </reference>
  <reference>
    <citation>Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.</citation>
    <PMID>24315724</PMID>
  </reference>
  <reference>
    <citation>EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26.</citation>
    <PMID>22449293</PMID>
  </reference>
  <reference>
    <citation>Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 Dec 10;361(24):2342-52. doi: 10.1056/NEJMoa0906598.</citation>
    <PMID>19966341</PMID>
  </reference>
  <reference>
    <citation>Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):699-708. doi: 10.1056/NEJMoa1207541. Epub 2012 Dec 8.</citation>
    <PMID>23216615</PMID>
  </reference>
  <reference>
    <citation>Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31. Erratum in: N Engl J Med. 2014 Jan 23;370(4):390.</citation>
    <PMID>23991658</PMID>
  </reference>
  <reference>
    <citation>Caldeira D, Rodrigues FB, Barra M, Santos AT, de Abreu D, Gonçalves N, Pinto FJ, Ferreira JJ, Costa J. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart. 2015 Aug;101(15):1204-11. doi: 10.1136/heartjnl-2015-307489. Epub 2015 Jun 2. Review.</citation>
    <PMID>26037103</PMID>
  </reference>
  <reference>
    <citation>Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692-4.</citation>
    <PMID>15842354</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Association for Innovation and Biomedical Research on Light and Image</investigator_affiliation>
    <investigator_full_name>CHAD</investigator_full_name>
    <investigator_title>Prof. Francisco Batel Marques</investigator_title>
  </responsible_party>
  <keyword>Anticoagulation</keyword>
  <keyword>Anticoagulants</keyword>
  <keyword>Vitamin K antagonists</keyword>
  <keyword>Warfarin</keyword>
  <keyword>Low molecular weight heparin</keyword>
  <keyword>Direct oral anticoagulants</keyword>
  <keyword>dabigatran</keyword>
  <keyword>rivaroxaban</keyword>
  <keyword>apixaban</keyword>
  <keyword>edoxaban</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Thromboembolism</keyword>
  <keyword>Venous Thromboembolism</keyword>
  <keyword>Heart Valve Diseases</keyword>
  <keyword>Arrhythmia</keyword>
  <keyword>Heart Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Embolism and Thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

